Continuous Quality Improvement (CQI) Pilot Study Evaluating the Utility of an Educational Video

Inclusion Criteria: * Subjects with a clinical diagnosis of actinic keratoses with at least 6 clinically-diagnosed actinic keratoses on the face, bald scalp, arms, upper chest, OR dorsal hands classified as grade I, mild (slightly palpable actinic keratoses, more easily felt than seen), and II, moderate (moderately thick hyperkeratotic actinic keratoses, easily felt). Exclusion Criteria: * Patients using interferon or interferon inducers, immunomodulators, cytotoxic or immunosuppressor drugs, corticosteroids, retinoids, or investigational drugs within 4 weeks prior to enrollment. * Patients who have been treated with any topical drug for actinic keratoses lesions less than 8 weeks prior to enrollment. * Patients with invasive tumors within the treated area (e.g. invasive squamous cell carcinoma) * Patients who have exhibited any dermatological disease within the treated or adjacent (3 cm distance) area at the time of screening. * Patients who have known allergies to fluorouracil (5-FU).